Phillip Gambel

Array ( [id] => 13139871 [patent_doc_number] => 10087256 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-10-02 [patent_title] => Method of making an anti-CD40 antibody [patent_app_type] => utility [patent_app_number] => 15/401856 [patent_app_country] => US [patent_app_date] => 2017-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 40 [patent_figures_cnt] => 55 [patent_no_of_words] => 24178 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15401856 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11851738 [patent_doc_number] => 20170226230 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-10 [patent_title] => 'ANTI-COMPLEMENT C1S ANTIBODIES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/385735 [patent_app_country] => US [patent_app_date] => 2016-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 49 [patent_figures_cnt] => 49 [patent_no_of_words] => 53257 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15385735 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12253132 [patent_doc_number] => 09925262 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-03-27 [patent_title] => 'Kits comprising formulations of anti-C5 antibodies' [patent_app_type] => utility [patent_app_number] => 15/384788 [patent_app_country] => US [patent_app_date] => 2016-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 42697 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15384788 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15054913 [patent_doc_number] => 10457745 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-10-29 [patent_title] => Anti-complement C1s antibodies [patent_app_type] => utility [patent_app_number] => 15/385610 [patent_app_country] => US [patent_app_date] => 2016-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 4 [patent_no_of_words] => 65147 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15385610 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11866198 [patent_doc_number] => 20170233483 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-17 [patent_title] => 'ANTI-CD40 ANTIBODIES AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 15/384003 [patent_app_country] => US [patent_app_date] => 2016-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 31375 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15384003 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17407186 [patent_doc_number] => 11248055 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-15 [patent_title] => Polypeptides inhibiting CD40L [patent_app_type] => utility [patent_app_number] => 15/778677 [patent_app_country] => US [patent_app_date] => 2016-11-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 8 [patent_no_of_words] => 31758 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 414 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15778677 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13856393 [patent_doc_number] => 10189907 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-01-29 [patent_title] => Polynucleotides encoding anti-KIT antibodies [patent_app_type] => utility [patent_app_number] => 15/361936 [patent_app_country] => US [patent_app_date] => 2016-11-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 28 [patent_no_of_words] => 80651 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15361936 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11471257 [patent_doc_number] => 20170058039 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-02 [patent_title] => 'ANTI-CD40 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 15/341085 [patent_app_country] => US [patent_app_date] => 2016-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 38780 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15341085 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11499236 [patent_doc_number] => 20170073421 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-16 [patent_title] => 'Therapeutic Antibodies' [patent_app_type] => utility [patent_app_number] => 15/341550 [patent_app_country] => US [patent_app_date] => 2016-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 28019 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15341550 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15915413 [patent_doc_number] => 10654935 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-05-19 [patent_title] => Methods of treating SLE with anti-OX40L antibodies [patent_app_type] => utility [patent_app_number] => 15/340497 [patent_app_country] => US [patent_app_date] => 2016-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 7 [patent_no_of_words] => 65256 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 128 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15340497 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11436117 [patent_doc_number] => 20170037137 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-09 [patent_title] => 'SYNERGISTIC COMBINATIONS OF OX40L ANTIBODIES FOR THE TREATMENT OF GVHD' [patent_app_type] => utility [patent_app_number] => 15/333517 [patent_app_country] => US [patent_app_date] => 2016-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 94141 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15333517 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11589713 [patent_doc_number] => 20170114125 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-27 [patent_title] => 'METHODS OF TREATING DISEASE USING ANTIBODIES TO LYSOPHOSPHATIDIC ACID' [patent_app_type] => utility [patent_app_number] => 15/331881 [patent_app_country] => US [patent_app_date] => 2016-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 31498 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15331881 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17287094 [patent_doc_number] => 11203634 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-21 [patent_title] => Methods of treating age-related macular degeneration in a patient comprising administering an anti-C5a antibody [patent_app_type] => utility [patent_app_number] => 15/766753 [patent_app_country] => US [patent_app_date] => 2016-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 19 [patent_no_of_words] => 16681 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15766753 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15422631 [patent_doc_number] => 10544229 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-01-28 [patent_title] => Agonistic antibodies specifically binding CD40 and methods of use [patent_app_type] => utility [patent_app_number] => 15/281670 [patent_app_country] => US [patent_app_date] => 2016-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 34417 [patent_no_of_claims] => 45 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15281670 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13929147 [patent_doc_number] => 20190048089 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-14 [patent_title] => Antagonistic Antibodies Specifically Binding Human CD40 and Methods of Use [patent_app_type] => utility [patent_app_number] => 15/763673 [patent_app_country] => US [patent_app_date] => 2016-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26525 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15763673 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11866196 [patent_doc_number] => 20170233482 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-17 [patent_title] => 'COMBINATION THERAPY' [patent_app_type] => utility [patent_app_number] => 15/276591 [patent_app_country] => US [patent_app_date] => 2016-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 15225 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15276591 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13371937 [patent_doc_number] => 20180237509 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-23 [patent_title] => METHODS OF TREATING ADAMTS13 DEFICIENCIES AND CONGENITAL THROMBOTIC THROMBOCYTOPENIA IN PEDIATRIC PATIENTS [patent_app_type] => utility [patent_app_number] => 15/762207 [patent_app_country] => US [patent_app_date] => 2016-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8350 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15762207 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11364085 [patent_doc_number] => 20170002067 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-05 [patent_title] => 'Anti-C5a Binding Moieties With High Blocking Activity' [patent_app_type] => utility [patent_app_number] => 15/267902 [patent_app_country] => US [patent_app_date] => 2016-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 23976 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15267902 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12387792 [patent_doc_number] => 09963503 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-05-08 [patent_title] => Methods of producing anti-C5a antibodies [patent_app_type] => utility [patent_app_number] => 15/262697 [patent_app_country] => US [patent_app_date] => 2016-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 53658 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15262697 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15422629 [patent_doc_number] => 10544228 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-01-28 [patent_title] => Nucleic acids encoding antibody polypeptides that antagonize CD40 [patent_app_type] => utility [patent_app_number] => 15/259828 [patent_app_country] => US [patent_app_date] => 2016-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 8 [patent_no_of_words] => 32144 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 299 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15259828 [rel_patent_id] =>[rel_patent_doc_number] =>)